तुलना करने के लिए मीट्रिक्स | 2257 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध2257पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −4.4x | −1.2x | −0.4x | |
PEG अनुपात | −0.06 | −0.07 | 0.00 | |
क़ीमत/बुक | −6.4x | 4.7x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 86.5x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 93.8% | 51.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 25.8% | 8.8% | अनलॉक करें |
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs. The company’s therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors. The company is also developing STP122G for the treatment of coagulation disorders; STP125G to treat hypertriglyceridemia; and STP144G for the treatment of complement diseases. In addition, it is developing STP247G to treat complement-mediated immunologic diseases; STP237G for the treatment of hypertension in combination with familial hypertriglyceridemia; and STP136G to treat hypertension. The company was founded in 2007 and is based in Wan Chai, Hong Kong.